EMEA-002181-PIP01-17
Key facts
| Active substance |
|
| Therapeutic area |
Ophthalmology
|
| Decision number |
P/0333/2017
|
| PIP number |
EMEA-002181-PIP01-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of presbyopia
|
| Route(s) of administration |
Ophthalmic use
|
| Contact for public enquiries |
Allergan Pharmaceuticals International Limited
E-mail: ml-eu_reg_affairs@allergan.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|